Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Nanotamoxifen Delivery System: Toxicity Assessment After Oral Administration and Biodistribution Study After Intravenous Delivery of Radiolabeled Nanotamoxifen.

Shukla J, Dinda AK, Srivastava AK, Srivastava K, Mittal BR, Bandopadhyaya GP.

World J Nucl Med. 2016 Jan-Apr;15(1):7-11. doi: 10.4103/1450-1147.167594.

2.

Ongoing Use of Data and Specimens From National Cancer Institute-Sponsored Cancer Prevention Clinical Trials in the Community Clinical Oncology Program.

Minasian LM, Tangen CM, Wickerham DL.

Semin Oncol. 2015 Oct;42(5):748-63. doi: 10.1053/j.seminoncol.2015.07.006. Epub 2015 Jul 10. Review.

3.

Clinical Trial of Acolbifene in Premenopausal Women at High Risk for Breast Cancer.

Fabian CJ, Kimler BF, Zalles CM, Phillips TA, Metheny T, Petroff BK, Havighurst TC, Kim K, Bailey HH, Heckman-Stoddard BM.

Cancer Prev Res (Phila). 2015 Dec;8(12):1146-55. doi: 10.1158/1940-6207.CAPR-15-0109. Epub 2015 Sep 21.

4.

Hormonal therapies in young breast cancer patients: when, what and for how long?

Christinat A, Di Lascio S, Pagani O.

J Thorac Dis. 2013 Jun;5 Suppl 1:S36-46. doi: 10.3978/j.issn.2072-1439.2013.05.25.

5.

Not all depression is created equal: sex interacts with disease to precipitate depression.

Nemeth CL, Harrell CS, Beck KD, Neigh GN.

Biol Sex Differ. 2013 Apr 17;4(1):8. doi: 10.1186/2042-6410-4-8.

6.

Choices for young women at intermediate risk of breast cancer.

Iqbal J, Narod SA.

Curr Oncol. 2012 Jun;19(3):e112-4. doi: 10.3747/co.19.925. No abstract available.

7.

Quality of life over time in women diagnosed with ductal carcinoma in situ, early-stage invasive breast cancer, and age-matched controls.

Jeffe DB, Pérez M, Liu Y, Collins KK, Aft RL, Schootman M.

Breast Cancer Res Treat. 2012 Jul;134(1):379-91. doi: 10.1007/s10549-012-2048-y. Epub 2012 Apr 8.

8.

Nonhormonal management of hot flashes for women on risk reduction therapy.

Sideras K, Loprinzi CL.

J Natl Compr Canc Netw. 2010 Oct;8(10):1171-9.

9.

Changes in sexual problems over time in women with and without early-stage breast cancer.

Pérez M, Liu Y, Schootman M, Aft RL, Schechtman KB, Gillanders WE, Jeffe DB.

Menopause. 2010 Sep-Oct;17(5):924-37. doi: 10.1097/gme.0b013e3181d5dd26.

10.

Growth hormone and insulin-like growth factor-I in the transition from normal mammary development to preneoplastic mammary lesions.

Kleinberg DL, Wood TL, Furth PA, Lee AV.

Endocr Rev. 2009 Feb;30(1):51-74. doi: 10.1210/er.2008-0022. Epub 2008 Dec 15. Review. Erratum in: Endocr Rev. 2012 Dec;33(6):1038.

11.

Estrogen receptor genotypes influence hot flash prevalence and composite score before and after tamoxifen therapy.

Jin Y, Hayes DF, Li L, Robarge JD, Skaar TC, Philips S, Nguyen A, Schott A, Hayden J, Lemler S, Storniolo AM, Flockhart DA, Stearns V.

J Clin Oncol. 2008 Dec 20;26(36):5849-54. doi: 10.1200/JCO.2008.16.8377. Epub 2008 Nov 17.

12.

Amenorrhea in premenopausal women on the doxorubicin-and-cyclophosphamide-followed-by-docetaxel arm of NSABP B-30 trial.

Swain SM, Land SR, Ritter MW, Costantino JP, Cecchini RS, Mamounas EP, Wolmark N, Ganz PA.

Breast Cancer Res Treat. 2009 Jan;113(2):315-20. doi: 10.1007/s10549-008-9937-0. Epub 2008 Feb 27.

13.

Supplemental Content

Support Center